An interventional study of Timing of pegfilgrastim administration in Pegfilgrastim, Bone Pain and Chemotherapy, sponsored by Guangdong Provincial People's Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Guangdong Provincial People's Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Breast Neoplasms by Guangdong Provincial People's Hospital — 13 open to participants now, 14 under way, 3 of them phase 3. Breast Neoplasms · Guangdong Provincial People's Hospital.
Among the 24 studies in Breast Neoplasms by Guangdong Provincial People's Hospital, this one is the 13th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2023, is one of 8 with no phase, reaches primary completion later than 3 of the 13 other live ones, and was the 14th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →13 of the 24 studies in Breast Neoplasms by Guangdong Provincial People's Hospital are open now, in 1 country. Recruiting first, the newest first:
Guangdong Provincial People's Hospital · Sites in China
Ages 18–75 · Women only
Guangdong Provincial People's Hospital · Sites in China
Ages 18–60 · Women only
Guangdong Provincial People's Hospital · Sites in China
Ages 18–80
Guangdong Provincial People's Hospital · Sites in China
Ages 18–70
Guangdong Provincial People's Hospital · Sites in China
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 12 · Phase 3 5
First in 2012; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 156 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 160 across the 23 interventional studies, 301 across the 1 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Guangdong Provincial People's Hospital is the lead sponsor of 237 studies on the registry; 102 are open to participants now.
6 of the studies in Breast Neoplasms by Guangdong Provincial People's Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07077018Guangdong Provincial People's HospitalFasting-Mimicking Diet as an Adjunct to Neoadjuvant Chemotherapy for Hormone-Receptor-Positive Breast Cancer | 2026-12-30 |
| NCT06811870Guangdong Provincial People's HospitalA Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer Patients | 2026-12-31 |
| NCT06825975Guangdong Provincial People's HospitalA Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Triple-Negative and HER2+ Breast Cancer Patients | 2026-12-31 |
| NCT06825949Guangdong Provincial People's HospitalA Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Hormone Receptor Positive Breast Cancer Patients | 2026-12-31 |
| NCT05189496Guangdong Provincial People's HospitalHyperbaric Oxygen in the Prevention of Radiation Pneumonitis | 2026-12-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 24 studies in Breast Neoplasms by Guangdong Provincial People's Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
According to the National Comprehensive Cancer Network (NCCN) guidelines, patients receiving high-risk or moderate-risk febrile neutropenia (FN) chemotherapy with at least one risk factor should receive prophylactic granulocyte colony-stimulating factors (G-CSFs). However, pegfilgrastim-induced bone pain (PIBP) remains a common and significant clinical issue without a satisfactory solution. Studies have reported that the incidence rate of PIBP is 71.3%, with severe bone pain occurring in 27.0% of cases. Currently, the available data on PIBP treatment are limited to case reports, reviews, and small randomized controlled trials.
The NCCN guidelines recommend preventive oral non-steroidal anti-inflammatory drugs or antihistamines as the treatment for PIBP. However, even with these preventive measures, the incidence rate of PIBP remains high at 61.1%, with severe bone pain occurring in 19.2% of cases. Severe bone pain can significantly impact the patient's health-related quality of life (HRQol), leading to potential refusal of pegfilgrastim administration and subsequent dose reduction in effective chemotherapy. Ultimately, this may have negative implications for tumor cure rates and patient survival.
Based on previous literature, it appears that delaying the administration of pegfilgrastim may be associated with a lower incidence of PIBP. Therefore, our study aims to investigate the correlation between the timing of pegfilgrastim administration and the occurrence of PIBP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pegfilgrastim is administrated 24 hours after completing the chemotherapy in the 24-hour group.
Other: Timing of pegfilgrastim administration
Pegfilgrastim is administrated 48hours after completing the chemotherapy in the 48-hour group.
Other: Timing of pegfilgrastim administration
Pegfilgrastim is administrated 72 hours after completing the chemotherapy in the 72-hour group.
Other: Timing of pegfilgrastim administration
Timing of pegfilgrastim administration
The area under the curve (AUC) for daily worst bone pain score for days 1 through 5 (day 1 is defined as the day of pegfilgrastim administration) in cycle 1.
Measured by Brief Pain Inventory-Short Form
Time frame: Days 1 through 5 (day 1 is defined as the day of pegfilgrastim administration).
Incidence of bone pain
Measured by Brief Pain Inventory-Short Form
Time frame: Days 1 through 5 (day 1 is defined as the day of pegfilgrastim administration).
Incidence of severe bone pain
Measured by Brief Pain Inventory-Short Form
Time frame: Days 1 through 5 (day 1 is defined as the day of pegfilgrastim administration).
Duration of bone pain and severe bone pain
Measured by Brief Pain Inventory-Short Form
Time frame: Days 1 through 5 (day 1 is defined as the day of pegfilgrastim administration).
Impact of bone pain on daily life and other aspects.
Measured by Brief Pain Inventory-Short Form
Time frame: Days 1 through 5 (day 1 is defined as the day of pegfilgrastim administration).
Change From Baseline in European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) Score.
The EORTC QLQ-C30 is a questionnaire to assess quality of life (QoL), it is composed of 30 questions (items) resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, pain), and 6 single items (dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status indicate a better quality of life; a positive change from baseline indicates improvement. Lower scores on the symptom and single-item scales indicate a better quality of life; a negative change from baseline indicates improvement.
Time frame: Before pegfilgrastim administration in the first chemotherapy cycle (baseline), day 7 after each cycle of pegfilgrastim administration.
Change From Baseline in European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Breast Cancer-23 (EORTC QLQ-BR23) Score.
The EORTC QLQ-BR23 is a questionnaire to assess quality of life (QoL), it is composed of 23 questions (items) resulting in 4 functional scales (Body Image, Future Perspective, Sexual Functioning, Sexual Enjoyment) and 4 symptom scales (Systemic Therapy Side Effects, Upset by Hair Loss, Arm Symptoms, Breast Symptoms). All of the scales measures range in score from 0 to 100. Higher score for the functioning scales indicate a better quality of life; a positive change from baseline indicates improvement. Lower scores on the symptom scales indicate a better quality of life; a negative change from baseline indicates improvement.
Time frame: Before pegfilgrastim administration in the first chemotherapy cycle (baseline), day 7 after each cycle of pegfilgrastim administration.
Change From Baseline in European Quality of Life-Five Dimension-Five Level Scale (EQ-5D-5L) Score.
The EQ-5D-5L consists of a descriptive system that defines health in terms of five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a visual analog scale (VAS) for respondents to rate their current health status from 0 (worst health) to 100 (best imaginable health). A unique EQ-5D-5L health state (or profile) for each patient was generated by combining the results for the dimensions, consisting of a five-digit code. The health states were then converted to a preference-weighted summary score (weights derived from the general population), or EQ-5D-5L health utility index, with higher scores indicating better outcomes, and a positive change from baseline indicates improvement.
Time frame: Before pegfilgrastim administration in the first chemotherapy cycle (baseline), day 7 after each cycle of pegfilgrastim administration.
Analgesic use
According to the diary written by the patient about the use of the analgesic.
Time frame: Days 1 through 5 (day 1 is defined as the day of pegfilgrastim administration).
The area under the curve (AUC) for daily worst bone pain score for days 1 through 5 (day 1 is defined as the day of pegfilgrastim administration) in every cycle.
Measured by Brief Pain Inventory-Short Form
Time frame: Days 1 through 5 (day 1 is defined as the day of pegfilgrastim administration).
Leukocyte count
Measured by blood routine tests.
Time frame: Patients do blood routine tests on the seventh day of each chemotherapy cycle (Each cycle lasts 28 days, and day 1 denotes the day of chemotherapy completion) and when necessary.
Incidence of febrile neutropenia
Measured by thermometer and blood routine tests.
Time frame: Patients monitor their oral temperature daily, and do blood routine tests on the seventh day of each chemotherapy cycle (Each cycle lasts 28 days, and day 1 denotes the day of chemotherapy completion) and when necessary.
Incidence of neutropenia
Measured by blood routine tests.
Time frame: Patients do blood routine tests on the seventh day of each chemotherapy cycle (Each cycle lasts 28 days, and day 1 denotes the day of chemotherapy completion) and when necessary.
Absolute neutrophil count
Measured by blood routine tests.
Time frame: Patients do blood routine tests on the seventh day of each chemotherapy cycle (Each cycle lasts 28 days, and day 1 denotes the day of chemotherapy completion) and when necessary.
Plan to share: No
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for May 2025, 24 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 24 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guangdong Provincial People's Hospital →